multiple sclerosis ms chronic inflammatory demyelinating disease affects central nervous system cns several therapies exist although known cure common initial course disease relapsingremitting subtype characterized unpredictable attacks relapses followed periods relative remission new signs disease activity years many people subtype begin experience neurologic decline without acute relapses happens called secondary progressive multiple sclerosis less common courses disease primary progressive decline beginning without attacks progressiverelapsing steady neurologic decline superimposed attacks different therapies used patients experiencing acute attacks patients relapsingremitting subtype patients progressive subtypes patients without diagnosis ms demyelinating event managing various consequences ms primary aims therapy returning function attack preventing new attacks preventing disability medical treatment medications used management ms may several adverse effects many possible therapies still investigation time different alternative treatments pursued many people despite fact little supporting comparable replicated scientific study stem cell therapy studied article focuses therapies standard ms borderline forms ms particular treatments excluded administration high doses intravenous corticosteroids methylprednisolone routine therapy acute relapses administered period three five days wellestablished efficacy promoting faster recovery disability however insufficient evidence indicate significant impact longterm disability corticosteroid steroids administered orally similar effectiveness safety profile treating ms symptoms intravenous consequences severe attacks respond corticosteroids might treated several diseasemodifying treatments approved regulatory agencies different countries including us food drug administration fda european medicines agency ema pharmaceuticals medical devices agency pmda japanese ministry health labour welfare medications approved fda include interferons monoclonal antibodies ofatumumab ublituximab immunomodulators glatiramer acetate mitoxantrone dimethyl diroximel siponimod approved march cladribine approved march ozanimod approved march daclizumab later interferon first drug ever approved ms soon followed interferon glatiramer interferon injected either weekly intramuscular injection three times week subcutaneous injection depending commercial interferon injected subcutaneously every second pegylated form interferon introduced brand name plegridy available subcutaneous peginterferon beta attaches polyethylene glycol interferon molecules allowing longer lasting biological effects body decreasing frequency administration every two interferon beta balances expression pro antiinflammatory agents brain reduces number inflammatory cells cross overall therapy interferon beta leads reduction neuron moreover also thought increase production nerve growth factor consequently improve neuronal glatiramer acetate mixture random polymers four amino acids antigenically similar myelin basic protein component myelin sheath nerves competes presentation cells injected subcutaneously daily mitoxantrone immunosuppressant also used cancer chemotherapy approved ms year whereas natalizumab monoclonal antibody initially approved given intravenous infusion monthly intervals case natalizumab every three months case fingolimod receptor modulator became first oral drug approved fda followed teriflunomide drug inhibits synthesis pyrimidine disrupts interaction cells antigen presenting fingolimod teriflunomide taken daily single one oral drug dimethyl fumarate improved version fumaric acid already existing drug approved fda another oral drug cladribine approved russia australia application rejected fda emea due safety concerns led pharmaceutical discontinue commercialization withdraw marketing march ocrelizumab approved united states treatment primary progressive multiple sclerosis also used adults treatment relapsing forms multiple sclerosis include clinically isolated syndrome relapsingremitting disease active secondary progressive ocrelizumab approved use european union january siponimod cladribine approved united states treatment secondary progressive multiple siponimod approved use european union january treatment adults secondary progressive multiple cladribine approved use european union august treatment adults relapsing forms multiple october diroximel fumarate vumerity approved medical use united march ozanimod zeposia approved united states treatment relapsing multiple sclerosis include clinically isolated syndrome relapsingremitting disease active secondary progressive disease april monomethyl fumarate bafiertam approved united states treatment relapsing forms multiple sclerosis include clinically isolated syndrome relapsingremitting disease active secondary progressive disease ponesimod ponvory approved medical use united states march ublituximab briumvi approved medical use united states december interferons glatiramer acetate available injectable forms cause skin reactions injection site specially subcutaneous skin reactions vary greatly clinical presentation may include bruising erythema pain pruritus irritation swelling extreme cases cutaneous usually appear within first month treatment albeit frequence importance diminish six months mild skin reactions usually impede treatment whereas necroses appear around patients lead discontinuation also time visible dent injection site due local destruction fat tissue known lipoatrophy may interferons subclass cytokines produced body illnesses influenza order help fight infection responsible many symptoms influenza infections including fever muscle aches fatigue many patients report influenzalike symptoms hours taking interferonbeta usually improve within hours symptoms related temporary increase reaction tends disappear months treatment symptoms treated overthecounter nonsteroidal antiinflammatory drugs ibuprofen reduce fever another common transient secondary effect interferonbeta functional deterioration already existing symptoms deterioration similar one produced ms patients due heat fever stress uhthoffs phenomenon usually appears within hours treatment common initial months treatment may last several symptom specially sensitive worsening interferonbeta also reduce numbers white blood cells leukopenia lymphocytes lymphopenia neutrophils neutropenia well affect liver cases effects nondangerous reversible cessation reduction nevertheless recommendation patients monitored laboratory blood analyses including liver function tests ensure safe use glatiramer acetate generally well common secondary effect glatiramer acetate skin problem postinjection reaction manifested flushing chest tightness heart palpitations breathlessness anxiety usually lasts less thirty minutes require additional mitoxantrone therapy may associated immunosuppressive effects liver damage however dangerous side effect doserelated cardiac toxicity careful adherence administration monitoring guidelines therefore essential includes obtaining echocardiogram complete blood count treatment decide whether therapy suitable patient risks great recommended mitoxantrone discontinued first signs heart damage infection liver dysfunction heart problems mainly systolic dysfunction appear patients leukemia prevalence soon approval natalizumab withdrawn market manufacturer linked three cases rare hazardous neurological condition called progressive multifocal leukoencephalopathy pml opportunistic infection neurological progressive symptoms caused replication jc virus glial cells initial cases taking natalizumab combination interferon safety review drug returned market monotherapy ms special prescription may cases pml reported patients taken natalizumab none taken drug combination diseasemodifying treatments previous use ms treatments increases risk pml estimated prevalence pml cases per thousand natalizumab around ms patients pml die remaining importantly clinical trials fingolimod gave rise side effects hypertension bradycardia macular edema elevated liver enzymes reduction lymphocyte teriflunomide considered safe drug nevertheless reports liver failure teriflunomide also known dangerous fetal common secondary effects dimethyl fumarate clinical trials flushing gastrointestinal problems generally mild occurred frequently first month dimethyl fumarate leads reduction white blood cell count levels monitored patients reported cases opportunistic infections clinical moreover fumaric acid also used treat psoriasis another autoinmune disorder long term safety data years use without indication dangerous secondary disproportionality analysis based realworld adverse event reports faers none fda approved dmts associated higher risk cancerrelated reported earliest clinical presentation rrms clinically isolated syndrome cis single attack single symptom cis subacute attack suggestive demyelination patient fulfill criteria diagnosis multiple early treatment reduce hazard conversion first attack clinically definite multiple however difficult make firm conclusions best treatment especially regarding benefit safety early treatment given lack studies directly comparing disease modifying therapies longterm monitoring patient medications modestly effective decreasing number attacks rrms reducing accumulation brain lesions measured using gadoliniumenhanced magnetic resonance imaging interferons glatiramer acetate roughly equivalent reducing relapses approximately safe profile make firstline nevertheless patients responsive therapies known ms patients nonresponsive beta one factors related nonrespondance presence high levels interferon beta neutralizing antibodies interferon therapy specially interferon induces production neutralizing antibodies usually second months treatment treated moreover subset rrms patients specially active ms sometimes called rapidly worsening ms normally nonresponders immunomodulators treated either mitoxantrone natalizumab considered highly effective terms relapse rate reduction halting disability progression however considered secondline treatment risk adverse natalizumab halves risk relapsing compared interferons overall efficacy mitoxantrone also highly useful reduce attacks disability generally considered longterm therapy due severe cardiac official guidelines yetwhen use diseasemodifying oral treatments due recent believe probably reduce usage firstline treatments longterm safety interferons glatiramer acetate probably slow recommended momentwhen oral treatments mainly offered cases patients use existing treatments due needle phobia reasons perceived inefficacy interferons glatiramer could also used patients taking natalizumab developed jc virus antibodies therefore increased risk dimethyl fumarate potentially one interesting oral drugs due long term data use psoriasis points towards good safety cochrane systematic review found moderate quality evidence reduction number people rrms relapses twoyear treatment period dimethyl fumarate versus placebo well low quality evidence reduction worsening disability overall need higher quality studies longer update relative effectiveness different treatments unclear compared placebo small number direct comparisons interferons glatiramer acetate indicate similar effects small differences effects relapse rate disease progression magnetic resonance imaging alemtuzumab natalizumab fingolimod may effective drugs reducing relapses short term people natalizumab interferon rebif may reduce relapses compared placebo interferon avonex interferon betaseron glatiramer acetate mitoxantrone may also prevent evidence relative effectiveness reducing disability progression medications associated adverse effects may influence risk benefit studies longterm effects drugs specially newest existing data effects interferons glatiramer acetate indicate earlyinitiated longterm therapy safe related better oral contraceptive pills contradictory results different studies regarding effect decreasing relapse rate women multiple certain medications ms symptoms carbamazepine used treat spasms pain modafinil used treat fatigue make oral contraceptive pills less mitoxantrone shown positive effects people secondary progressive progressive relapsing courses moderately effective reducing progression disease frequency relapses people two medication approved us secondary progressive progressive relapsing multiple sclerosis however causes dosedependent cardiac toxicity limits longterm use also approved europe natalizumab shown efficacy approved secondary progressive ms relapses studies use secondary progressive progressive relapsing ms support slows progression disease although effective reducing number treatment primary progressive multiple sclerosis ppms problematic many patients respond available therapy treatment approved specifically use form disease several trials investigating efficacy different drugs ppms without positive results network metaanalysis immunomodulator immunosuppressant agents suggested evidence effective preventing disability progression people progressive drugs tested include interferon beta mitoxantrone glatiramer acetate people ppms also included trials azathioprine methotrexate intravenous immunoglobulin hematopoietic stem cell march ocrelizumab approved united states treatment primary progressive multiple sclerosis also used treatment relapsing forms multiple sclerosis include clinically isolated syndrome relapsingremitting disease active secondary progressive disease occupational therapy occupational therapy play important factor managing symptoms multiple sclerosis symptoms limited include tremors gait impairment difficulty transfers ots help manage tremors outfitting patient using small passive weights decrease intensity tremors regard gait impairment occupational therapists help develop specific gait training program evaluate appropriate adaptive equipment devices consider need powered mobility occupational therapists skilled transferring help multiple sclerosis transferring abilities well providing training transferring techniques evaluation assistive symptoms ms improved include fatigue spasticity depression bladder dysfunction neurological symptoms symptoms improved physical therapy medication physical therapists show strengthening exercises ways stretch ultimately making daily tasks easier reduces fatigue muscle strength increases flexibility exercise therapy proscribed safely without increased relapse best supported rehabilitation intervention reducing fatigue improving muscle strength mobility quality life according overview cochrane systematic reviews drug therapy neurorehabilitation shown ease burden symptoms even though neither influence disease progression symptoms efficacy treatments still aquatic therapy also shown alleviate symptoms multiple sclerosis aquatic cycling aerobic exercise safe effective way increase muscular strength endurance circulation ms patients aquatic therapy decreased patients pain aided depressionfatigue improved cardiorespiratory fitness overall modality beneficial impacts daily life activities quality although relatively studies rehabilitation general effectiveness conducted team specialists clearly demonstrated diseases head patient neurologic deficits multidisciplinary approach key limiting overcoming however particular difficulties specifying core team people ms may need help almost health profession service neurologists mainly involved diagnosis ongoing management multiple sclerosis exacerbations comprehensive rehabilitation process patients multiple sclerosis generally managed physiatrists allied treatments speech language occupational also help manage symptoms maintain quality life treatment neuropsychiatric symptoms emotional distress clinical depression involve mental health professionals therapists psychologists neuropsychologists help evaluate manage cognitive multidisciplinary approaches shown effective increasing activity levels participation multiple studies investigating information provision support patient understanding participation suggest interventions written information decision aids coaching educational programmes may increase patient knowledge evidence effect decision making quality life mixed low due paucity randomized controlled studies limited evidence overall efficacy individual therapy though good evidence specific approaches psychology therapies particularly cognitive behavioral energy conservation effective specifically psychological interventions seem useful treatment depression evidence effectiveness uses treatment cognitive impairments vocational counseling less cognitive training alone combined neuropsychological interventions may show positive effects memory attention though firm conclusions possible given small sample numbers variable methodology interventions outcome effectiveness palliative approaches addition standard care uncertain due lack difficult specific types rehabilitation beneficial therapies tailored meet individuals specific regards wellbeing physical therapy focused gait training vital maximizing ms patient participation via reduction fatigue walking activities daily living gait training performed overground ie gym room outside uneven ground treadmills less commonly using roboticassisted devices roboticassisted body weightsupported treadmill training may effective therapeutic option ms patients severe walking contrast overground gait training may effective improving gait speed ms patients less severe equineassisted therapies therapeutic horseback riding hippotherapy additional treatments positively influence balance quality life people another effective modality used physical therapy improve gait balance ms patients aquatic therapy patients ms perform walking functional exercises balance training stretches aquatic therapy improve overall gait performance aquatic therapy improve gait ms patients also dynamic balance postural historically individuals ms advised participation physical activity due worsening however direction expert participation physical activity safe proven beneficial persons research supported rehabilitative role physical activity improving muscle bowel general conditioning quality effectiveness interventions including exercise specifically prevention falls people ms uncertain evidence effect balance function depending person activities may include resistance walking swimming yoga tai chi determining appropriate safe exercise program challenging must carefully individualized person sure account contraindications elevated core temperature leading increased symptom presentation noted exercise due variations circadian body temperature throughout day due heat exposure including warm temperatures warm showers sun bathing etc care taken overheat person ms course exercise evidence cooling measures effective allowing greater degree exercise cold showers cold water limb immersion applying ice packs drinking cold beverages strategies effective attempting decrease core temperature postexercise method precooling prior physical activity heat march us food drug administration fda authorized marketing new device indicated use shortterm treatment gait deficit due mild moderate symptoms multiple sclerosis device intended used prescription adjunct supervised therapeutic exercise program patients years age device called portable neuromodulation stimulator pons neuromuscular tongue stimulator consists nonimplantable apparatus generate electrical pulses stimulation trigeminal facial nerves via tongue provide treatment motor pons device portable nonimplantable device delivers mild neuromuscular electrical stimulation dorsal surface multiple sclerosis cause variety symptoms including changes sensation hypoesthesia muscle weakness abnormal muscle spasms impaired movement difficulties coordination balance problems speech known dysarthria swallowing dysphagia visual problems nystagmus optic neuritis diplopia fatigue acute chronic pain syndromes bladder bowel difficulties cognitive impairment emotional symptoms mainly depression time symptom different treatment options symptoms ataxia tremor sensory losses proven evidence effect respiratory muscle training heterogeneous low quality effect important outcomes like cough efficacy pneumonia quality life epileptic seizures potentially serious comorbidity people multiple sclerosis uncommon nonetheless present often general population however currently lack evidence efficacy safety antiepileptic medication specifically people multiple possibly secondary result demyelinating lesions uncommon potentially serious complaint research directions ms treatments include investigations ms pathogenesis heterogeneity research effective convenient tolerable new treatments rrms creation therapies progressive subtypes neuroprotection strategies search effective symptomatic advances last decades led recentwhen approval several oral drugs drugs expected gain popularity frequency use expense previously existing oral drugs stillwhen investigation notable example laquinimod announced august focus third phase iii trial mixed results previous similarly studies aimed improve efficacy ease use already existing therapies use novel preparations case pegylated version longer life normal interferon therefore studied given less frequent doses similar efficacy existing completion robust twoyear study shown pegylated interferon greater efficacy decreasing relapse rate disability progression compared placebo ms preliminary data suggestedwhen mycophenolate mofetil antirejection immunosuppressant medication might benefits people multiple sclerosis however systematic review found limited evidence available insufficient determine effects mycophenolate mofetil therapy interferon people monoclonal antibodies drugs family natalizumab also raised high levels interest research alemtuzumab daclizumab monoclonal antibodies ocrelizumab ofatumumab shown benefit study potential treatments update nevertheless use also accompanied appearance potentially dangerous adverse effects importantly opportunistic related investigations recentwhen development test jc virus antibodies might help predict patients greater risk developing progressive multifocal leukoencephalopathy taking monoclonal antibodies probably going role treatment disease future believed small due risks associated update another research strategy evaluate combined effectiveness two main rationale polytherapy ms involved treatments target different mechanisms disease therefore use necessarily moreover synergies drug potentiates effect another also possible nevertheless also appear important drawbacks antagonizing mechanisms action potentiation deleterious secondary several clinical trials combined therapy none shown positive enough effects merit consideration viable treatment likewise effective treatments progressive variants diseaseneeds update many newest drugs well development probably going evaluated therapies ppms spms improved effectiveness compared previously existing drugs may eventually lead positive result groups medications influence voltagegated sodium ion channels investigation potential neuroprotective strategy hypothesized role sodium pathological process leading axonal injury accumulating disability currently insufficient evidence effect sodium channel blockers people growing developments area medical imaging mri allowing better reviews understandings ms patients treat case effective finally regarding neuroprotective specially regenerative treatments stem cell therapy research considered high importance moment promise future therapeutic study found promising results relapsingremitting ms research vascular surgeon paolo zamboni suggested ms involves vascular process referred chronic cerebrospinal venous insufficiency ccsvi veins brain constricted found ccsvi patients ms theory received important attention media among people ms specially concern raised zambonis research neither blinded controlled additionally assumptions pathophisiology disease may backed known also studies either found relationship found much less strong raised objections hypothesis ccsvi originating liberation procedure criticized possibly resulting serious complications deaths benefits currentlywhen recommended use proposed treatment unless effectiveness confirmed controlled research ccsvi fast tracked researchers unable confirm whether ccsvi role causing ms patients may use complementary alternative medicine although numbers vary greatly depending definition alternative medicine united states estimated ms patient populations use least one complementary alternative medicine treatment symptomatic controlcitation needed evidence effectiveness treatments cases weak examples treatments used patients include dietary supplementation vitamin calcium vitamin antioxidants rationale behind use vitamin supplementation studies show association vitamin deficiency increasing progression ms well antiinflammatory effects vitamin however available evidence suggests vitamin supplementation irrespective form dose used provides apparent benefit people ms measures relapse recurrence disability worsening mri lesions effects quality life fatigue antioxidant therapy studies shown reactive oxidative species lead formation multiple sclerosis lesions antioxidants help induce neuroprotective immunomodulatory probably clear disease modifying factor worse smoking therefore quit smoking alternative treatments include relaxation techniques herbal medicine including use medical hyperbaric selfinfection hookworm known generally helminthic therapy bee venom therapy reflexology regarding characteristics users frequently women ms longer time tend disabled moreover also lower levels satisfaction conventional clinical guidelines clinical guidelines documents aim guiding decisions criteria specific areas healthcare defined authoritative examination current evidence evidencebased medicine httpsenwikipediaorgwikimanagementofmultiplesclerosis